Anti-CD23 Recombinant Antibody Lumiliximab(Lumiliximab) (CAT#: TAB-760)

Recombinant chimeric (primate/human) antibody expressed in CHO. Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator. The drug is a chimeric antibody from Macaca irus and Homo sapiens.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Normal Tissue
RNA Expression

Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • primate
  • Derivation
  • Chimeric (primate/human)
  • Type
  • IgG1 - kappa
  • Species Reactivity
  • Human
  • Applications
  • Suitable for use in IP, IF, FuncS, FC, Neut, ELISA, ICC and most other immunological methods.
  • CAS
  • 357613-86-6
  • Generic Name
  • lumiliximab
  • UNII
  • 8Z13S29R5A
  • MW
  • 47.75 kDa
  • Related Disease
  • Allergic asthma

Product Property

  • Purity
  • >95.0%. Determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • At -20°C for one year.

Target

  • Alternative Names
  • lumiliximab;357613-86-6;IDEC-152;P5E8;gomiliximab;FCER2;Fc fragment of IgE, low affinity II, receptor for (CD23);CD23A, Fc fragment of IgE, low affinity II, receptor for (CD23A) , FCE2;low affinity immunoglobulin epsilon Fc receptor;CD23;CLEC4J;BLAST-2;CD

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Lumiliximab"

Afuco™ Anti-CD23 ADCC Recombinant Antibody (Lumiliximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (primate/human) antibody expressed in CHO. Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator. The drug is a chimeric antibody from Macaca irus and Homo sapiens.

See other products for "CD23"

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-760. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare